
Bristol Myers Squibb (BMS) has announced positive results from the TRANSCEND FL phase 2 study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel) …

For people living with aggressive blood cancers, CAR T-cell therapy offers hope for a longer, healthier life, and for some, …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

